The understanding of molecular and genomic features has changed the way of diagnosing and treating this heterogeneous disease, allowing for the selection of more effective and personalized treatments in several subsets of EGFR-mutated NSCLC patients [9]. Here, EGFR is linked to non-small cell lung carcinoma.